15th Mar 2016 09:52
LONDON (Alliance News) - Stem cell therapy development company ReNeuron Group PLC on Tuesday said the first patient has been treated with is cell therapy candidate for retinitis pigmentosa, a blindness-causing disease.
The procedure on the first patient, which involves a single injection of ReNeuron's hRPC cells under the retina, was conducted at Massachusetts Eye & Ear in Boston, a teaching affiliate of Harvard Medical School.
The study, which will cover 15 patients in total, is the first clinical trial activity undertaken by ReNeuron in the US.
"The dosing of the first patient in the Phase I/II clinical trial of our cell therapy candidate for retinitis pigmentosa marks another significant milestone for ReNeuron. With the start of this study, we are also delighted to have commenced clinical development activities in the US, a major target market," said Olav Hellebo, ReNeuron's chief executive.
ReNeuron shares were down 0.7% to 3.35 pence on Tuesday morning.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
RENE.L